2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
16
Other hematologic neoplasm
13
Plasma cell
8
Thoracic
7
Gynecologic
3
Gastrointestinal
3
Dermatologic
2
Tumor-Agnostic
1
Myeloid
1
Head & Neck
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
Cyclophosphamide
261
fludarabine phosphate
233
Azacitidine
182
fludarabine
181
Busulfan
176
Cytarabine
155
Imatinib Mesylate
152
Mycophenolic Acid
148
Tacrolimus
146
Whole-Body Irradiation
142
Peripheral Blood Stem Cell Transplantation
140
Cyclosporine
110
Antilymphocyte Serum
108
Melphalan
107
Methotrexate
105
Filgrastim
101
Decitabine
98
nilotinib
94
venetoclax
79
ruxolitinib
79
Dasatinib
68
Granulocyte Colony-Stimulating Factor
66
Stem Cell Transplantation
63
Thiotepa
60
Radiotherapy
60
thymoglobulin
52
Specimen Handling
49
Etoposide
49
Clofarabine
46
Cord Blood Stem Cell Transplantation
45
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Maintenance
×
Myeloid
×
Clear all
NCT07572929
2026-05-07
PREeMPT
Medical College of Wisconsin
Phase 2
Not yet recruiting
450 enrolled